Comparative Pharmacology
Head-to-head clinical analysis: A HYDROCORT versus DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A HYDROCORT versus DEXAMETHASONE.
A-HYDROCORT vs DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
None Documented
None Documented
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Category C
Category D/X
Corticosteroid
Corticosteroid